DCAL · Healthcare · Biotechnology
Composite scorecard: 31/100 — Quality 42 · Valuation 33 · Momentum 0
| Share price | ₹190.83 |
| Market cap | ₹3,071 Cr |
| P/E ratio | 31.4 |
| P/B ratio | 0.5 |
| ROCE | 2.9% |
| Book value | ₹426.90 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,932 Cr | ₹97 Cr | 19.0% |
| 2025 | ₹2,712 Cr | ₹3 Cr | 17.0% |
| 2024 | ₹2,616 Cr | ₹-153 Cr | 11.0% |
| 2023 | ₹2,413 Cr | ₹-30 Cr | 14.0% |
| 2022 | ₹2,141 Cr | ₹18 Cr | 15.0% |
Dishman Carbogen Amcis Limited provides contract research and manufacturing services for the pharmaceutical and healthcare industries worldwide. The company operates through Contract Research and Manufacturing Services and Marketable Molecules segments. It offers cholesterol and vitamin D analogs; generic active pharmaceutical ingredients for diagnostics, ophthalmic treatments, laxatives, organophosphate antidotes; ammonium, phosphonium; quats, phosphoranes, and wittig reagents; cholesterol and lanolin-related products; sterile injectables; and softgel formulations, as well as hand and body wa